Tvardi Therapeutics (NASDAQ:TVRD) Cut to “Sell” at Wall Street Zen

Wall Street Zen lowered shares of Tvardi Therapeutics (NASDAQ:TVRD) from a hold rating to a sell rating in a research note released on Saturday.

A number of other equities research analysts have also recently issued reports on TVRD. Piper Sandler cut shares of Tvardi Therapeutics from an “overweight” rating to a “neutral” rating in a report on Monday, October 13th. BTIG Research decreased their price target on shares of Tvardi Therapeutics from $55.00 to $15.00 and set a “buy” rating for the company in a report on Monday, October 13th. Weiss Ratings restated a “sell (e+)” rating on shares of Tvardi Therapeutics in a report on Tuesday, October 14th. Cantor Fitzgerald cut shares of Tvardi Therapeutics from an “overweight” rating to a “neutral” rating in a research note on Monday, October 13th. Finally, Barclays set a $5.00 target price on shares of Tvardi Therapeutics and gave the company an “equal weight” rating in a research note on Monday, October 13th. Three equities research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus target price of $55.50.

Tvardi Therapeutics Trading Down 6.2%

Shares of TVRD opened at $6.17 on Friday. Tvardi Therapeutics has a one year low of $5.65 and a one year high of $43.65. The stock has a fifty day moving average price of $29.86.

Tvardi Therapeutics (NASDAQ:TVRD) last released its quarterly earnings results on Thursday, August 14th. The company reported ($1.00) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.49). Tvardi Therapeutics had a negative net margin of 678.79% and a negative return on equity of 565.83%.

Hedge Funds Weigh In On Tvardi Therapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. JPMorgan Chase & Co. acquired a new position in Tvardi Therapeutics in the second quarter valued at about $39,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. acquired a new position in Tvardi Therapeutics in the second quarter valued at about $43,000. Headlands Technologies LLC acquired a new position in Tvardi Therapeutics in the second quarter valued at about $80,000. New York State Common Retirement Fund acquired a new position in Tvardi Therapeutics in the second quarter valued at about $92,000. Finally, Bank of America Corp DE acquired a new position in Tvardi Therapeutics in the second quarter valued at about $399,000. 44.66% of the stock is currently owned by institutional investors and hedge funds.

About Tvardi Therapeutics

Cara Therapeutics, Inc, an early commercial-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body’s peripheral nervous system and immune cells.